Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).
Aim(s): To assess the activity and toxicity of platinum-based chemotherapy in patients with advanced NECs. To evaluate the potential correlation between some clinical (primary site, somatostatin receptor expression, timing of the platinum-based regimen introduction) and biological factors (ERCC-1, grading and Ki67) with the clinical outcomes.
Materials and methods: The tumours were defined according to WHO 2000 and TNM 2006 classifications. Response rate (RR), time to progression (TTP), toxicity, and survival were calculated. The tissue tumour samples were centrally (IEO) analysed to detect Ki67, and excision repair cross-complementig group-1 (ERCC-1).
Presenting Author: MD FRANCESCA SPADA
To read results and conclusion, please login ...
Further abstracts you may be interested in
Introduction: Conventional chemotherapy does not have a well-defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs). Various regimens were evaluated. Cisplatin or carboplatin combined with etoposide are usually indicated in poorly differentiated (PD) NECs. Some evidence exists for oxaliplatin activity in WD and PD NECs, combined with capecitabine or gemcitabine.
Conference: 7th Annual ENETS Conference (2010)
Presenting Author: Francesca Spada
Introduction: Phase III trials of sunitinib, everolimus and octreotide lar confirmed that these drugs improved progression-free survival (PFS) in well-differentiated PNET, low/intermediate grade pNET and well-differentiated midgut NETs, respectively. CLARINET is the 1st phase III study that showed PFS benefit of SSA, lanreotide, in both P- and midgut NET and in Ki-67 5-10%.
Conference: 11th Annual ENETS Conference (2014)
Category: Medical treatment - Targeted therapies
Presenting Author: PhD Paula J Fonseca
Introduction: PRRT is a well-documented and well-established treatment for metastatic neuroendocrine tumours. However retrospective studies detailing the efficacy of PRRT are lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: PRRT-Ablative therapies-Endoscopic treatment
Presenting Author: Dr Haamid Jan
Introduction: GEP NETs WHO classification 2010 describes well-differentiated tumors grade 1 and grade 2 and neuroendocrine carcinomas grade 3 with high mitotic index over 20 mitoses /10 HPF or Ki 67 over 20%. Pulmonary neuroendocrine tumor classification 2004 describes typical and atypical carcinoid tumor and small-cell and large-cell neuroendocrine carcinomas with mitotic index over 10 mitoses/ 10 HPF.
Conference: 10th Annual ENETS Conference (2013)
Category: Pathology, grading, staging
Presenting Author: M.D., MBA Eva Sedlackova
Introduction: In Romania, treatment with somatostatin analogs (SSA) for neuroendocrine tumors (NETs) is based on the National Clinical Practice Guideline for the Diagnostic and Treatment of NETs and is reimbursed by the National Health Insurance Company since 2008.
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: MD, PhD, Prof. Fica Simona